INHIBITORS
-
Health Canada approves Alhemo (concizumab) for FIX inhibitors
Montreal – May 23, 2023 – The Canadian Hemophilia Society has learned that Health Canada recently approved Alhemo (concizumab) for the treatment of people, ages...
-
2022 CHS Annual Report
Please CLICK HERE to access the 2022 CHS Annual Report. Should you want to consult the complete Financial Statements, you can do so by clicking HERE.
-
Update on coagulation products – current and in the pipeline
To access charts informing you of products in the PIPELINE, please CLICK HERE. To access charts informing you of CURRENT coagulation products, please CLICK HERE....
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia Consortium.
-
Hearing the patient voice on therapy choice: FVIII or non-FVIII
by the Canadian Association of Nurses in Hemophilia Care – Ontario Region* and Sarah Crymble, Ontario Hemophilia Provincial Coordinator Treatment for patients with hemophilia A...